Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
- First Online:
- Cite this article as:
- Gault, V.A., McClean, P.L., Cassidy, R.S. et al. Diabetologia (2007) 50: 1752. doi:10.1007/s00125-007-0710-4
- 538 Downloads
Gastric inhibitory polypeptide (GIP) receptor antagonism with (Pro3)GIP improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure/function in ob/ob mice. This study examined the ability of (Pro3)GIP to counter the development of obesity, insulin resistance and diabetes in mice fed high-fat and cafeteria diets.
Materials and methods
Young Swiss TO mice on standard chow or high-fat, cafeteria or high-carbohydrate diets received daily injections of either saline or (Pro3)GIP (25 nmol kg-1day-1) over 16 weeks. Food intake, body weight, and circulating glucose and insulin were measured frequently. At 16 weeks, glucose tolerance, insulin sensitivity, HbA1c, circulating hormones and plasma lipids were assessed. Adipose tissue, liver and muscle were excised and weighed, and their histology and triacylglycerol content were further examined.
(Pro3)GIP significantly reduced body weight, enhanced locomotor activity, and improved HbA1c, glucose tolerance, beta cell responsiveness and insulin sensitivity in mice fed high-fat and cafeteria diets (p < 0.05 to p < 0.01). Similarly, (Pro3)GIP significantly reduced plasma corticosterone and triacylglycerols (p < 0.05 to p < 0.001), while glucagon, resistin and adiponectin were unchanged. (Pro3)GIP decreased adipose tissue mass (p < 0.01) and the triacylglycerol content of liver, muscle and adipose tissue (p < 0.01 to p < 0.001). Adipocyte size and liver morphology were partially normalised. (Pro3)GIP did not significantly affect any of these parameters in mice fed a high-carbohydrate diet.
(Pro3)GIP protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. This highlights chemical GIP receptor antagonism as a new possibility for the treatment of obesity and associated metabolic disturbances.
KeywordsDiet-induced obesityGastric inhibitory polypeptideGastric inhibitory polypeptide antagonistInsulin resistanceObesity-related diabetes(Pro3)GIP
area above the curve
gastric inhibitory polypeptide
An epidemic of diabetes is poised to afflict affluent and developing societies throughout the world, fuelled by ageing demographics and the recent explosion of obesity and related insulin resistance that now sees increasing numbers of children presenting with type 2 diabetes . Obesity is associated with the ‘metabolic syndrome’, characterised by insulin resistance, glucose intolerance, hypertension, dyslipidaemia and atherosclerosis. Without intervention, this will lead to full-blown type 2 diabetes, severely eroding quality of life and greatly reducing life expectancy. Therefore, novel approaches which aim to improve the responsiveness of peripheral tissues to insulin and aid restraint of rising obesity are of important therapeutic interest. Despite its classic role as an insulin-releasing intestinal hormone, recent data indicate that gastric inhibitory polypeptide (GIP) exerts effects on adipose tissue and lipid metabolism to promote fat deposition and insulin resistance [2,3]. There is now accumulating evidence to suggest a possible role for GIP receptor antagonists in the alleviation of obesity and insulin resistance [4, 5].
Although involvement of GIP in the aetiology and metabolic disturbances of obesity has long been suspected, this aspect has been very largely overlooked due to its greater recognition as an important entero-insular hormone and glucose-dependent stimulator of insulin secretion [3, 6–8]. Nevertheless, data gathered over time plus more recent observations provide quite compelling evidence that GIP is a key link between consumption of affluent energy-rich high-fat diets and causation of insulin resistance, obesity and type 2 diabetes [4, 5].
Many pieces of indirect evidence support the involvement of GIP in obesity and its various manifestations. First, ingestion of fat has very strong and protracted stimulatory effects on GIP secretion that greatly exceed effects of ingested carbohydrate and protein . Second, consumption of a high-fat diet results in K cell hyperplasia, increased GIP gene expression and intestinal GIP, resulting in increased circulating GIP concentrations [10–13]. Animal models and humans with obesity diabetes have been reported also to exhibit elevated circulating GIP and exaggerated K cell secretory responses [14–16]. At the cellular level, GIP receptors have been demonstrated on adipocytes . These mediate various anabolic effects of GIP, including stimulation of glucose uptake, lipoprotein lipase activity, fatty acid synthesis and fatty acid incorporation into adipose tissue [18–21]. At the same time, GIP inhibits both glucagon- and isoproterenol-induced lipolysis, thereby further favouring deposition rather than mobilisation of fat stores [22, 23]. Consistent with these various observations, both normal and obese diabetic ob/ob mice with genetic knockout of the GIP receptor are protected from diet-induced obesity .
Chemical ablation of GIP signalling using a specific GIP receptor antagonist, (Pro3)GIP, in obese diabetic ob/ob mice has unequivocally demonstrated how GIP receptor antagonism can provide a novel approach to the treatment and prevention of obesity-related diabetes [4, 24]. In the present study, we have investigated the ability of (Pro3)GIP to counter the development of obesity, insulin resistance and diabetes in mice fed high-fat and cafeteria diets. An additional group fed a high-carbohydrate diet was employed to examine the importance of nutritional energy source.
Materials and methods
Animals and diet regimens
Male NIH Swiss mice at 6–8 weeks were obtained from Harlan UK (Shaw’s Farm, Blackthorn, UK). Animals were age-matched, divided into groups and housed individually in an air-conditioned room at 22 ± 2°C with a 12 h light:12 h darkness cycle (08:00–20:00 hours). Control animals received a standard rodent maintenance diet composed of 10% fat, 30% protein and 60% carbohydrate ad libitum (percentage total energy of 12.99 kJ/g; Trouw Nutrition, Northwich, UK). The high-fat diet was composed of 45% fat, 20% protein and 35% carbohydrate (26.15 kJ/g; Special Diet Services, Witham, UK), and was available ad libitum to mice in this group, referred to as ‘high-fat mice’ throughout the remainder of this article. Cafeteria-fed animals, referred to as ‘cafeteria mice’, received standard rodent maintenance diet ad libitum (12.99 kJ/g; Trouw Nutrition) alongside a 6 day rotation of the following food pairs: tuna fish and Pringles; peanut butter and chocolate digestives; Madeira cake and milk chocolate; cereal and luncheon meat; sausages and corned beef; and cheese and marzipan. The overall composition of the cafeteria diet consumed during the study period was 34% fat, 18% protein and 48% carbohydrate (23.74 kJ/g). The high-carbohydrate diet was composed of 10% fat, 20% protein and 70% carbohydrate (18.8 kJ/g; Special Diet Services), and was available ad libitum to mice in this group, referred to as ‘high-carbohydrate mice’. Drinking water was freely available to all groups of animals. All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986.
Experimental protocols for in vivo studies
Over a 16 week period, dietary-intervention animals received once-daily i.p. injections (17:00 hours) of either saline vehicle (0.9% [w/v] NaCl) or (Pro3)GIP (25 nmol/kg body weight; Sigma-Genosys, Cambridge, UK). Control animals received once-daily i.p. injections of saline. Food intake and body weight were recorded every 3–4 days for all groups, except the cafeteria fed animals, which were recorded daily. Plasma glucose and insulin concentrations were monitored at weekly intervals. Blood for the measurement of HbA1c and plasma for measurement of cholesterol, triacylglycerols, glucagon, corticosterone, adiponectin and resistin were taken on week 16. Intraperitoneal glucose tolerance (18 mmol/kg body weight) and insulin sensitivity (50 U/kg body weight) tests were performed at the end of the study period. All acute experiments commenced at 10:00 hours. In a separate series, pancreatic tissues were excised at the end of the 16 week treatment period, weighed and processed for measurement of insulin following extraction with 5 ml/g of ice-cold acid ethanol (750 ml ethanol, 235 ml water, 15 ml 12 mol/l HCl). Brown adipose tissue, white adipose tissue (epididymal, peri-renal and subcutaneous), liver and skeletal muscle were also excised, weighed and stored for histology or measurement of triacylglycerol content. In a final set of experiments, locomotor activity tests were performed in high-fat mice after 4 weeks of treatment with either (Pro3)GIP or saline, as assessed from total distance traversed in an open field (120 × 120 cm surface area with 35 cm high walls), calculated from measurement of line breaks (15 × 15 cm grid). Animals were given 3 min each in the arena and tested over 5 days .
Blood samples taken from the cut tip of the tail vein of conscious mice at the times indicated in the figures were immediately centrifuged using a Beckman microcentrifuge (Beckman Instruments, High Wycombe, UK) for 30 s at 13,000×g. The resulting plasma was then aliquoted into fresh Eppendorf tubes and stored at −20°C prior to analysis. Plasma glucose was assayed by an automated glucose oxidase procedure  using a Beckman Glucose Analyser II (Beckman Instruments, Galway, Ireland). Plasma and pancreatic insulin were assayed by a modified dextran-coated charcoal RIA . HbA1c was determined using a commercially available kit purchased from Chirus (Watford, UK). Plasma and tissue triacylglycerol and cholesterol levels were measured using a Hitachi Automated Analyser 912 (Boehringer, Mannheim, Germany). Serum glucagon and plasma adiponectin and resistin concentrations were measured using RIA kits purchased from Linco Research (St Charles, MI, USA). Corticosterone concentrations were similarly measured using a kit supplied by MP Biomedicals (Heidelberg, Germany). All analyses were carried out according to instructions supplied by the various manufacturers. Lipid and protein contents of extracted tissues were measured as described previously . Protein was determined using a Dc Protein Kit (Bio-Rad, Hercules, CA, USA).
Excised white adipose tissue and liver were fixed in 4% (w/v) paraformaldehyde/PBS and embedded in paraffin. Sections (8 μm) were cut and mounted on slides as described elsewhere . White adipose tissue was stained with haematoxylin and counterstained with eosin, while liver was stained with Oil Red O and counterstained with haematoxylin. Stained slides were viewed under a microscope (Nikon Eclipse E2000; Diagnostic Instruments, Sterling Heights, MI, USA) attached to a JVC camera Model KY-F55B (JVC, London, UK).
Results are expressed as means±SEM. Data were compared using ANOVA, followed by a Student–Newman–Keuls post hoc test. AUC analyses were calculated using the trapezoidal rule with baseline subtraction . A p value of less than 0.05 was considered to be statistically significant.
Effects of (Pro3)GIP on food intake, body weight, non-fasting plasma glucose and insulin and HbA1c concentrations
Effects of (Pro3)GIP on glucose tolerance
Effects of (Pro3)GIP on insulin sensitivity and pancreatic insulin content
Effects of (Pro3)GIP on circulating glucagon, corticosterone, adiponectin, resistin and lipid profile
Effects of (Pro3)GIP on adipose mass, tissue triacylglycerols and morphology of white adipose tissue and liver
Effects of (Pro3)GIP on locomotor activity
High-fat feeding had no significant effect on physical activity compared with a control diet (54.8 ± 2.4 vs 54.0 ± 3.6 line breaks per min, n = 9, respectively). However, mice treated with (Pro3)GIP exhibited significantly greater locomotor activity (67.1 ± 3.0 line breaks per min) compared with mice on the regular or high-fat diet (p < 0.05). The body weight of the (Pro3)GIP-treated group was also significantly decreased at this time.
In the present study, normal mice were given free access to two types of high-fat diet, one comprising a synthetic nutrient mix, and another made up of pairs of various cafeteria items presented in rotation. Such diets have been shown previously to result in increased intestinal and circulating GIP [10, 13, 30]. Consistent with these earlier observations, access to the high-fat diets resulted in increased food (energy) intake, progressive body weight gain, hyperglycaemia and hyperinsulinaemia with notable impairments of glucose tolerance, insulin secretion and insulin sensitivity at 16 weeks. At this time, the animals were visibly obese and exhibited elevated circulating concentrations of cholesterol and triacylglycerol. Adipose tissue mass was enhanced by about 40% and significant amounts of triacylglycerol were stored not only in hypertrophic adipocytes but also in liver and muscle. In comparison, an energy-rich synthetic high-carbohydrate diet induced minimal changes in body weight, fat deposition and regulation of blood glucose and lipids compared with control mice fed standard laboratory chow. This observation serves to illustrate well the clear-cut detrimental metabolic effects of diets deriving energy from fat as opposed to complex carbohydrates. Administration of (Pro3)GIP had no effect on the phenotype in the mice fed the high-carbohydrate diet.
Consistent with involvement of GIP in mediating the detrimental effects of high-fat feeding, daily GIP receptor antagonism using (Pro3)GIP had quite remarkable effects in protecting mice from consequences of either of the synthetic and cafeteria high-fat diets. Thus although administration of (Pro3)GIP during free access to high-fat diets did not affect energy intake, the excessive body weight gain was substantially decreased or even totally blocked following cafeteria feeding. In both groups, this was associated with decreases in adipose tissue mass, and adipocyte size was also remarkably decreased in the high-fat group. These animals also exhibited improved liver morphology and lesser deposition of triacylglycerol in adipose tissue, muscle and liver. These data point to crucial effects of GIP antagonism in enhancing energy expenditure in situations of high-fat feeding. Such a view is reinforced by studies conducted using GIP receptor knockout mice [2, 31]. Absence of similar actions following high-carbohydrate feeding in the present study is probably a reflection of the different metabolism of sugars and the fact that they are much weaker stimulators of GIP secretion and do not induce prominent changes in intestinal and circulating GIP . Nevertheless, the fact that the carbohydrate and energy content of this diet were only 17 and 45% greater than normal chow should not be overlooked.
Although an increase of energy expenditure might also reflect enhanced locomotor activity as suggested here and elsewhere , this is unlikely to be the only mechanism underlying weight loss in mice with ablated GIP signalling. Furthermore, overexpression of GIP in transgenic mice has actually been linked to enhanced locomotor activity . Accordingly, we believe that blockade of metabolic actions of GIP consequent to increased dietary fat intake is very largely responsible for energy dissipation. Thus, blockade of GIP receptor signalling can be expected to counter lipogenesis, promote lipolysis and importantly direct circulating lipids towards liver and skeletal muscle where they are used as a preferential energy substrate for fat oxidation . Although mice in the high-fat group that were treated with (Pro3)GIP continued to display hyperinsulinaemia, the subtle decrements in acute insulin secretion might also contribute to decreased fat accumulation. These various actions could explain the observed weight-reducing effects of (Pro3)GIP, which are essentially similar to those observed in GIP receptor knockout mice . The latter animals also exhibited a significant reduction of respiratory quotient during the light phase without change in oxygen consumption, indicating utilisation of fat as energy substrate rather than its accumulation in adipocytes. In addition, genetic ablation of the GIP receptor under situations of diminished insulin action has been shown to promote energy dissipation in liver, both by increasing hepatic fatty acid uptake through stimulating CD36 expression and by uncoupling nutrient oxidation to ATP generation through increasing uncoupling protein-2 . In skeletal muscle, ablation of GIP also increased both the expression and activity of the enzyme 3-hydroxyacyl-CoA dehydrogenase, which promotes fat oxidation.
In the present study, protection from high fat-induced obesity by (Pro3)GIP was accompanied by similar protection from development of hyperglycaemia, insulin resistance, glucose intolerance and hyperlipidaemia. Total cholesterol concentrations were also decreased in the high-fat group. Notwithstanding the obvious benefit of decreased adiposity, various mechanisms are likely to underlie the beneficial action of GIP receptor blockade. This is clearly indicated by similar desirable metabolic effects of (Pro3)GIP in ob/ob mice that were not accompanied by any change in body weight [4, 24]. These mechanisms are likely to centre around reversal of the biochemical abnormalities through which high fat intake and obesity cause insulin resistance . This action might result from decreased glucose production and/or increased glucose uptake and metabolism in liver, muscle or adipose tissue. Additionally, the observed changes in fat accumulation and metabolism of lipids at these sites will be involved. Thus, it is well known that inhibition of fat oxidation is correlated with increased intracellular triacylglycerol and interference of insulin signalling and decreased insulin action [35–37]. (Pro3)GIP can be expected to reverse such effects together with related adverse effects on the glucose–fatty acid cycle. The present study did not reveal appreciable changes in circulating glucagon, adiponectin or resistin following GIP receptor blockade. This contrasts with the idea that GIP might upregulate circulating resistin concentrations . Corticosterone was decreased, suggesting that inhibition of circulating or local production of corticosterone might be involved, as this promotes hepatic gluconeogenesis and antagonises insulin-stimulated glucose uptake in both skeletal muscle and adipose tissue .
The retention of beta cell function and insulin secretion in (Pro3)GIP-treated mice fed high-fat diets can be explained in terms of beta cell sparing due to decreased insulin demand as a result of improved insulin sensitivity, lower prevailing glucose levels and alleviation of chronic diet-induced GIP receptor activation. Glucagon-like peptide (GLP)-1 has many beneficial actions on beta cell function and we have some evidence that a compensatory enhancement of GLP-1 function, as observed in GIP receptor knockout mice , may contribute. Thus, although circulating GLP-1 was unchanged in ob/ob mice treated with (Pro3)GIP, administration of the GLP-1 antagonist exendin(9–39) had detrimental effects . Neither does there appear to be a distinguishable role for glucagon inhibition, as circulating concentrations were unchanged by (Pro3)GIP in the present study. Absence of beta cell glucose and lipid toxicity, together with a decrease in adiposity, will contribute to maintaining effective insulin secretory function and glucose homeostasis in (Pro3)GIP-treated mice fed a high-fat diet.
In conclusion, GIP receptor blockade using (Pro3)GIP acts in both diet-induced and genetic obesity-diabetes [4, 24] to decrease insulin resistance, improve glucose tolerance and enhance beta cell function. As shown in the present study, longer-term treatment also protects from obesity and associated abnormalities of circulating and tissue lipids induced by high-fat diets. There are very strong parallels between these effects and those of GIP receptor knockout ob/ob mice  and surgical bypass of GIP-secreting K cells in humans undergoing Roux-en-Y surgery for the treatment of gross obesity [41–44]. These various observations in diet-induced models and man suggest that GIP receptor antagonists, such as (Pro3)GIP, represent an exciting class of future drug for the treatment of obesity and alleviation of diabetes .
These studies were supported by a Project Grant from Diabetes UK and University of Ulster Research Strategy Funding.
Duality of interest
V. A. Gault, N. Irwin and P. R. Flatt are shareholders in Diabetica.